Oracle Introduces Oracle Health Sciences Mobile Clinical Research Associate
New Mobile Application Helps Clinical Research Associates Improve Efficiency, Optimize Clinical Development Process
Oracle Health Sciences today introduced Oracle Health Sciences Mobile Clinical Research Associate, which uses the power of mobile applications to help life sciences organizations compress clinical study cycle times and reduce costs by improving site monitoring efficiency and clinical research associate (CRA) productivity.
The mobile app, designed specifically for field use, is integrated with Oracle’s Siebel Clinical Trial Management System and Oracle Health Sciences Clinical Development Analytics to provide CRAs with real-time access to essential clinical trial information, decision support data, and comprehensive trip reports in either offline or connected modes.
Site-at-a-glance capabilities provide study site performance indicators in a single view so CRAs have up-to-date site progress information at their fingertips, enabling more efficient, proactive planning and more productive site visits.
Study and site alerts notify CRAs of key milestones, activities and potential problems for the study sites they are monitoring, enabling them to respond quickly to emerging issues.
The solution’s study site check-in feature automatically captures traveling CRAs’ site check-in details via geo-location capabilities and incorporates the information into the trip report, streamlining documentation for regulatory compliance.
Oracle Health Sciences Mobile Clinical Research Associate runs natively on iOS and is now available for Apple iPhone or Apple iPad via the Apple iTunes Store.
“With the increased pressure to reduce the time and cost of clinical trials, organizations need to optimize efficiency at every level. Unfortunately, despite the labor-intensive and critical role CRAs perform, most are still using traditional and antiquated tools to do their job. Oracle Health Sciences Mobile Clinical Research Associate is designed specifically to help CRAs improve productivity and lighten their load by enabling them to manage their responsibilities using a single mobile device,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
